Skip to main content

Advertisement

SpringerLink
Log in

Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells

  • Original Article
  • Published:
Applied Biochemistry and Biotechnology Aims and scope Submit manuscript

Abstract

Heat shock proteins (HSPs) are available and/or induced for the survival of all organisms, including eukaryotic, prokaryotic, and plants, from higher temperature stresses. They are the chaperone proteins that protect all cells against heat, as the name implies. In addition to thermal stress, they also protect them from chemical, physical, and other stresses, including exposure to oxidative stress, nutritional deficiencies, ultraviolet radiation, ethanol, viral infection, ischemia–reperfusion injury, and cancer-related stresses. They are classified based on their molecular weights in kDa, such as HSP90 and HSP70. In our label-free, high-throughput, quantitative LC–MS/MS-based proteomic studies of MDA-MB-231, human, triple-negative breast cancer cells, treated with electrical pulses (EP) and cisplatin (CsP), we identified a number of HSPs, such as HSP90AA1, and others to be significantly downregulated in EP + CsP, compared to CsP alone. This indicates that cells will undergo apoptotic cell death and hence could cause effective cancer cure/treatment. Considering that over 2 million new cases and over 600,000 deaths in 2020, of which ~ 15% are TNBC, heat shock proteins could be the untapped resources, available for the next biomarkers and/or inhibitors for new/additional therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data Availability

All data sources could be available to readers on request.

References

  1. Hyslop, et al. (2013). Population and target considerations for triple-negative breast cancer clinical trials. Biomarkers in Medicine, 7(1), 11–21.

    Article  CAS  Google Scholar 

  2. Klimczak, M., Biecek, P., Zylicz, A., & Zylicz, M. (2019). Heat shock proteins create a signature to predict the clinical outcome in breast cancer. Scientific reports, 9(1), 1–15.

    Article  CAS  Google Scholar 

  3. Velloso, et al. (2019). Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation. BMC Genomics, 20, 152.

    Article  Google Scholar 

  4. Clover, et al. (2020). Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for sharing practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019). European Journal of Cancer, 138, 30–40. https://doi.org/10.1016/j.ejca.2020.06.020

    Article  CAS  PubMed  Google Scholar 

  5. Hansen, H. F., Bourke, M., Stigaard, T., Clover, J., Buckley, M., O’Riordain, M., & Gehl, J. (2020). Electrochemotherapy for colorectal cancer using endoscopic electroporation: A phase 1 clinical study. Endoscopy international open, 8(2), E124.

    Article  Google Scholar 

  6. Mittal, L., Raman, V., Camarillo, I. G., & Sundararajan, R. (2017). Ultra-microsecond pulsed curcumin for effective treatment of triple negative breast cancers. BBRC, 491(4), 1015–1020.

    CAS  PubMed  Google Scholar 

  7. Mittal, L., Aryal, U. K., Camarillo, I. G., Ferreira, R. M., & Sundararajan, R. (2019). Quantitative proteomic analysis of enhanced cellular effects of electrochemotherapy with Cisplatin in triple-negative breast cancer cells. Scientific reports, 9(1), 1–16.

    Google Scholar 

  8. Calderwood, S. K. (2010). Heat shock proteins in breast cancer progression–A suitable case for treatment? International Journal of Hyperthermia, 26(7), 681–685.

    Article  CAS  Google Scholar 

  9. Ciocca, D. R., & Calderwood, S. K. (2005). Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell stress & Chaperones, 10(2), 86–103.

    Article  CAS  Google Scholar 

  10. Calderwood, S. K. (2017). Heat shock proteins and cancer: Intracellular chaperones or extracellular ligands? Philosophical Transactions of the Royal Society B: Biological Siences, 373, 20160524.

    Article  Google Scholar 

  11. Zoppino, F. C., Guerrero-Gimenez, M. E., Castro, G. N., & Ciocca, D. R. (2018). Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer. BMC Cancer, 18(1), 1–17.

    Article  Google Scholar 

  12. Calderon, P. B., Beck, R., & Glorieux, C. (2019). Targeting HSP90 family members: A strategy to improve cancer cell death. Biochemical Pharmacology, 164, 177–187.

    Article  Google Scholar 

  13. Lang, et al. (2019). Heat shock proteins are essential components in transformation and tumor progression: Cancer cell intrinsic pathways and beyond. International Journal of Molecular Sciences, 20, 4507.

    Article  CAS  Google Scholar 

  14. Pockley, A. G. (2003). Heat shock proteins as regulators of the immune response. Lancet, 362, 469–476.

    Article  CAS  Google Scholar 

  15. Neckers, L. (2007). Heat Shock Proten 90: The cancer chaperone. Journal of Biosciences, 32(3), 517–530.

    Article  CAS  Google Scholar 

  16. Jagadish, et al. (2016). Heat shock protein 70–2 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth. BMC Cancer, 16, 561.

    Article  Google Scholar 

  17. Biebl, M. M., & Buchner, J. (2019). Structure function and regulation of the HSP90 machinery. Cold Spring Harbor perspectives in biology, 11(9), a034017.

    Article  CAS  Google Scholar 

  18. Chehab, et al. (2015). Targeting HSP90 in urothelial carcinoma. Oncotarget, 6(11), 8454–8473.

    Article  Google Scholar 

  19. String-db.org. accessed March 2021.

  20. http://geneontology.org/docs/ontology-documentation/. Accessed July 2021.

  21. Genecards.org, accessed April 2021.

  22. Carmona-Saez, P., Chagoyen, M., Tirado, F., Carazo, J. M., & Pascual-Montano, A. (2007). GENECODIS: A web-based tool for finding significant concurrent annotations in gene lists. Genome biology, 8(1), R3.

    Article  Google Scholar 

  23. heatmap.ca, accessed June 2021

  24. Yun et al. Heat shock proteins: Agents of cancer development and therapeutic targets in anti-cancer therapy. Cells 2019.

  25. Cellular response to stress pathway https://reactome.org/PathwayBrowser/#/R-HSA-2262752

  26. Picard D. HSP facts & Literature – Cytosolic heat shock protein 90. https://www.picard.ch/downloads/Hsp90facts.pdf. Accessed Mar 2021.

  27. Li, et al. (2019). Interaction of hSP90AA1 with phospholipids stabilizes membranes under stress conditions. BBA-Molecules, 1861, 457–465.

    Article  CAS  Google Scholar 

  28. Kaur et al. (2015). Heat shock proteins in Triple-Negative breast cancer (TNBC) treatment. Ch 8 in Heat shock protein-based therapies, Heat shock proteins 9, Springer International Publishing Switzerland.

  29. Kou, et al. (2018). Simvastin functions as a heat shock protein 90 inhibitor against triple- negative breast cancer. Cancer Science, 109, 3272–3284.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Engineering Technology, Purdue University, West Lafayette, IN, 47907, USA

    Raji Sundararajan & Pragatheiswar Giri

  2. Aarupdaia Veedu Medical College, Pondicherry, India

    S. Madhivanan

  3. Savitha Medical College, Chennai, India

    Anita Ramesh

  4. Department of Electrical Engineering, IIT, Kharagpur, India

    N. K. Kishore

  5. School of Medical Sciences and Technology, IIT, Kharagpur, India

    M. Manjunatha

  6. Department of Biological Sciences, Purdue University, West Lafayette, IN, 47907, USA

    Ignacio G. Camarillo

  7. Purdue Center for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA

    Ignacio G. Camarillo

Authors
  1. Raji Sundararajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pragatheiswar Giri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Madhivanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anita Ramesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. K. Kishore
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Manjunatha
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ignacio G. Camarillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design: R Sundararajan.

Data analysis: P Giri, R Sundararajan, IG Camarillo.

Manuscript: All.

Corresponding author

Correspondence to Raji Sundararajan.

Ethics declarations

Ethics Approval and Consent to Participate

Not applicable.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sundararajan, R., Giri, P., Madhivanan, S. et al. Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells. Appl Biochem Biotechnol 194, 517–528 (2022). https://doi.org/10.1007/s12010-021-03703-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12010-021-03703-9

Keywords

Search

Navigation